These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23032938)

  • 41. Synthesis and SAR of Tetracyclic Inhibitors of Protein Kinase CK2 Derived from Furocarbazole W16.
    Kröger L; Daniliuc CG; Ensan D; Borgert S; Nienberg C; Lauwers M; Steinkrüger M; Jose J; Pietsch M; Wünsch B
    ChemMedChem; 2020 May; 15(10):871-881. PubMed ID: 32168422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity.
    Lindenblatt D; Applegate V; Nickelsen A; Klußmann M; Neundorf I; Götz C; Jose J; Niefind K
    J Med Chem; 2022 Jan; 65(2):1302-1312. PubMed ID: 34323071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
    Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
    Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a potent and selective chemical probe for the pleiotropic kinase CK2.
    Wells CI; Drewry DH; Pickett JE; Tjaden A; Krämer A; Müller S; Gyenis L; Menyhart D; Litchfield DW; Knapp S; Axtman AD
    Cell Chem Biol; 2021 Apr; 28(4):546-558.e10. PubMed ID: 33484635
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
    Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
    Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase.
    Chojnacki K; Lindenblatt D; Wińska P; Wielechowska M; Toelzer C; Niefind K; Bretner M
    Bioorg Chem; 2021 Jan; 106():104502. PubMed ID: 33317841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BID, an interaction partner of protein kinase CK2alpha.
    Olsen BB; Petersen J; Issinger OG
    Biol Chem; 2006 Apr; 387(4):441-9. PubMed ID: 16606343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New protein kinase CK2 inhibitors: jumping out of the catalytic box.
    Prudent R; Cochet C
    Chem Biol; 2009 Feb; 16(2):112-20. PubMed ID: 19246001
    [TBL] [Abstract][Full Text] [Related]  

  • 52. N-substituted Indole-2 and 3-carboxamide derivatives as inhibitors of human protein kinase CK2: in vitro assay and molecular modelling study.
    Olgen S; Gratz A; Kurt ZK; Jose J
    Acta Chim Slov; 2013; 60(3):628-35. PubMed ID: 24169717
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells.
    Yao K; Youn H; Gao X; Huang B; Zhou F; Li B; Han H
    Prostate; 2012 Sep; 72(13):1423-30. PubMed ID: 22290244
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
    Kufareva I; Bestgen B; Brear P; Prudent R; Laudet B; Moucadel V; Ettaoussi M; Sautel CF; Krimm I; Engel M; Filhol O; Borgne ML; Lomberget T; Cochet C; Abagyan R
    Sci Rep; 2019 Nov; 9(1):15893. PubMed ID: 31685885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In silico binding free energy predictability by using the linear interaction energy (LIE) method: bromobenzimidazole CK2 inhibitors as a case study.
    Bortolato A; Moro S
    J Chem Inf Model; 2007; 47(2):572-82. PubMed ID: 17381174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
    Hundsdörfer C; Hemmerling HJ; Götz C; Totzke F; Bednarski P; Le Borgne M; Jose J
    Bioorg Med Chem; 2012 Apr; 20(7):2282-9. PubMed ID: 22377675
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity.
    Cozza G; Zanin S; Sarno S; Costa E; Girardi C; Ribaudo G; Salvi M; Zagotto G; Ruzzene M; Pinna LA
    Biochem J; 2015 Nov; 471(3):415-30. PubMed ID: 26349539
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diversity-oriented synthesis of pyrazolo[4,3-b]indoles by gold-catalysed three-component annulation: application to the development of a new class of CK2 inhibitors.
    Hou Z; Oishi S; Suzuki Y; Kure T; Nakanishi I; Hirasawa A; Tsujimoto G; Ohno H; Fujii N
    Org Biomol Chem; 2013 May; 11(20):3288-96. PubMed ID: 23535832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
    Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
    Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.